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Abstract
Background: This study explored the effect of screening and treatment of refugees for latent tuberculosis infection
(LTBI) before entrance to the United States as a strategy for reducing active tuberculosis (TB). The purpose of this
study was to estimate the costs and benefits of LTBI screening and treatment in United States bound refugees prior
to arrival.
Methods: Costs were included for foreign and domestic LTBI screening and treatment and the domestic treatment
of active TB. A decision tree with multiple Markov nodes was developed to determine the total costs and number
of active TB cases that occurred in refugee populations that tested 55, 35, and 20 % tuberculin skin test positive
under two models: no overseas LTBI screening and overseas LTBI screening and treatment. For this analysis,
refugees that tested 55, 35, and 20 % tuberculin skin test positive were divided into high, moderate, and low LTBI
prevalence categories to denote their prevalence of LTBI relative to other refugee populations.
Results: For a hypothetical 1-year cohort of 100,000 refugees arriving in the United States from regions with high,
moderate, and low LTBI prevalence, implementation of overseas screening would be expected to prevent 440, 220,
and 57 active TB cases in the United States during the first 20 years after arrival. The cost savings associated with
treatment of these averted cases would offset the cost of LTBI screening and treatment for refugees from countries
with high (net cost-saving: $4.9 million) and moderate (net cost-saving: $1.6 million) LTBI prevalence. For low LTBI
prevalence populations, LTBI screening and treatment exceed expected future TB treatment cost savings (net cost
of $780,000).
Conclusions: Implementing LTBI screening and treatment for United States bound refugees from countries with
high or moderate LTBI prevalence would potentially save millions of dollars and contribute to United States TB
elimination goals. These estimates are conservative since secondary transmission from tuberculosis cases in the
United States was not considered in the model.
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Background
In the United States, most active tuberculosis (TB) cases
occur in foreign-born residents [1], and over 80 % of these
cases occur in persons thought to have acquired latent tu-
berculosis infection (LTBI) overseas [2]. This epidemio-
logic pattern has strongly influenced CDC’s determination
that identifying and treating LTBI is an important public
health intervention to reduce the prevalence of active pul-
monary TB cases [3].
Persons seeking entry into the United States for per-
manent residence (immigrants and refugees) receive a
mandatory overseas medical exam and are treated for
communicable diseases of public health significance
such as active, infectious TB prior to departure [4]. Since
LTBI is non-infectious, treatment for LTBI is not cur-
rently required. Medical exams are administered by
panel physicians. Panel physicians work in the immi-
grants’ and refugees’ country of origin in most instances
and are extended permission from the consular sections
of United States embassies to administer medical exams
that meet CDC standards (Technical Instructions) [5].
As a method for finding active TB in children under
age 15 who live in countries with TB prevalence greater
than 20 per 100,000, LTBI testing is performed. Those
with negative tests do not undergo further TB screening.
Immigrants and refugees age 15 and older (adults) are
not required to be tested for LTBI in their medical
exams, but they do receive mandatory chest radiographs
as a means of testing for active TB [5]. Refugees and im-
migrants with an abnormal chest radiograph, but nega-
tive results from sputum-smear microscopy for acid-fast
bacilli and culture for Mycobacterium tuberculosis, are
given a Class B1 TB classification that helps prioritize
them for further TB-related screening once they reach
the United States [6].
The result of this age-specific screening is that a ma-
jority of the approximately 500,000 immigrants and refu-
gees resettled annually are examined for active TB and if
diagnosed are treated prior to arriving in the United
States; however, they are not tested for LTBI overseas.
Therefore, this population of permanent entrants repre-
sents a potential reservoir of LTBI that can lead to TB
cases [2, 7, 8].
Immigrants pay for their own medical examinations
and treatments overseas, whereas the United States gov-
ernment pays the cost of refugees’ exams. The United
States government also pays for healthcare for at least
the first 8 months after a refugee’s arrival, and in many
states refugees are eligible for Medicaid for some time
past the first 8 months [9]. To address the long-term im-
pact of reactivated TB (progression from LTBI to active
TB), CDC has been considering adding voluntary LTBI
screening and treatment for adult refugees and immi-
grants to the current screening for active TB that is
already a part of the TB Technical Instructions issued to
panel physicians. In this evaluation, we focus on refu-
gees, in part because they typically have a longer interval
between examination and departure for resettlement in
the United States than do immigrants. The overseas refu-
gee medical screenings take place 2 to 6 months before
departure (Dr. Tarissa Mitchell, personal communication),
so overseas LTBI treatment of less than 6 months’ dur-
ation could be completed without delaying resettlement.
Such a proposed voluntary overseas LTBI program is
made feasible by a new drug regimen. Until recently,
standard LTBI treatment consisted of a daily dose of iso-
niazid for 9 months [10]. In 2011, CDC recommended use
of a 12-dose weekly isoniazid-rifapentine regimen (3HP)
to treat LTBI [11, 12]. The 12-dose regimen may be ad-
vantageous because it is administered weekly (with dir-
ectly observed therapy [DOT]) rather than daily, and
treatment is 3 months rather than 9 months in duration.
Compliance with voluntary LTBI treatment may be
higher for refugees living overseas than for those who
have resettled in the United States. While overseas, refu-
gees are able to direct much of their attention towards
receiving clearance to enter the United States. After ar-
rival, they have competing priorities (e.g., to find a home,
a job, enroll children into a school, learn a new language,
and generally acculturate to a new community) [13].
There is also some evidence of the success of other vol-
untary medical protocols; for example, an overseas pro-
gram of presumptive intestinal parasite treatment in
refugees has had a high participation rate [14].
After resettlement, all refugees are encouraged to re-
ceive a general follow-up medical exam at their local
public health department (PHD) which may include tests
for LTBI and an opportunity for treatment [15]. In
addition, PHDs are notified of refugees in their jurisdic-
tion who had an abnormal chest radiograph (1–15 % of
the population, depending on country of birth) during
the overseas exam so that these individuals may be pri-
oritized for TB-related testing [6, 16]. However, only
about 75 % of recently arrived refugees receive this
follow-up screening [7], and there is limited data to sug-
gest that screening practices vary across the country, so
that LTBI screening may be performed more frequently
in some jurisdictions than others [17–19]. Once they
have arrived in the United States, nearly a quarter of
those diagnosed with LTBI decline therapy, and about
70 % of refugees who start 9 months of isoniazid treat-
ment complete the therapy [20–23]. Therefore, a volun-
tary overseas LTBI testing and treatment program could
be expected to have a higher rate of enrollment and
completion than the current alternative.
We propose to analyze a voluntary overseas LTBI testing
and treatment program by estimating the costs and benefits
of two models : a new protocol of screening and treating all
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adult refugees for LTBI while still overseas, and the current
protocol of domestic LTBI screening and treatment.
IRB review and approval was not required. This study
was determined by CDC and Emory University to be re-
search not involving human subjects.
Methods
Model data
This analysis compared the costs and benefits of the
current domestic and proposed overseas programs to
screen for and treat LTBI. In both programs, we assume
that LTBI screening is performed using the tuberculin
skin test (TST), because it is the least expensive and
most widely available test. From the literature, we ob-
tained ranges of the proportion of both immigrants and
refugees with positive TST rates settling in the United
States [24–27]. We assumed that these data would pro-
vide possible ranges for the rates of positive TSTs in
U.S.-bound refugees.
In 2012 the majority of refugees that resettled in the
United States were screened in nine countries: Ethiopia,
Kenya, Uganda, Iraq, Jordan, Syria, Malaysia, Nepal, and
Thailand [28]. For our analysis we categorized refugees
into three hypothetical cohorts of 100,000 with high
(55 %), moderate (35 %), and low (20 %) rates of positive
TST results [24–27]. The respective categories reflect
how often the refugees test TST positive in relation to
other refugee populations. These TST results and the
sensitivity and specificity of the TST were used to esti-
mate LTBI prevalence. The estimate of LTBI prevalence
was then used to estimate the number of active TB cases
which might occur after domestic resettlement. The esti-
mated total program costs included treatment of active
TB cases and resources used to screen for and treat
LTBI, including TSTs, DOT labor, and medications.
We used data from the International Organization for
Migration to determine the prevalence of active TB in
refugee populations from the nine countries [28]. Coun-
tries were divided into high, moderate, and low preva-
lence of active TB based upon the following thresholds:
high (at least 600 cases per 100,000), medium (between
100 to 600 cases per 100,000) and low (less than 100
cases per 100,000). We assumed that the number of
adults treated for active TB during overseas screening
would be equal to the averages of active TB found within
each of these three regions.
Model overview
A decision tree model with Markov nodes was used to es-
timate the comparative costs and benefits of the current
domestic LTBI protocol with the proposed overseas LTBI
screening and treatment protocol. The model was devel-
oped using TreeAge Pro Software (Williamstown, MA,
U.S.). For each protocol, the model estimated the number
of refugees from each hypothetical cohort that would de-
velop active TB during a 20-year period after resettlement.
Our primary measure was the net benefit or cost from
implementing overseas screening programs which was cal-
culated using the following formula:
Total program cost with no overseas screening and treatment –
Total program cost with overseas screening or treatment:
The refugees entered into the decision tree were as-
sumed to have one of three TB conditions: active TB,
LTBI, or uninfected. First we modeled the current proto-
col where refugees are screened for LTBI after arrival in
the United States, and if positive, are offered treatment
at the local PHD [15]. Then, we modeled the proposed
overseas protocol that adds a TST to the mandatory
chest radiograph already administered to adults during
pre-departure medical exams [5]. If the TST was posi-
tive, and if there were no indications of active TB in the
chest radiograph, the adult refugee was assumed to be
diagnosed with LTBI and was offered treatment to be
completed prior to resettlement.
This analysis was conducted from both government and
health systems perspectives. All costs were presented in
2012 US dollars. Further, a 3 % annual discount rate was
used for all costs and health outcomes in accordance with
recommendations for economic evaluations of healthcare
programs [29]. Discounting was used to calculate the
present value of costs and benefits which occurred after
the first year of the model. In our base case analysis, we
used a 20-year analytic horizon. Background all-cause
mortality rates, grouped in 5-year increments (e.g., 30–34,
35–39), were incorporated using CDC data from 2005–
2010 for the general US population [30].
For the model, we needed estimates of LTBI “preva-
lence.” We estimated the prevalence from the percentage
of the population testing positive with the TST:
 (% TST test positive + specificity – 1)/(TST
sensitivity + specificity −1) [31].
– TST sensitivity was 89 %, an estimation that has
been used in CDC guidelines [32].
 We assumed an average specificity of 85 % in our
model because [33]:
– Inoculation with Bacillus Calmette-Guerin (BCG)
can affect the specificity of TST [34];
– Refugees who have received BCG vaccine once in
infancy test at 92 % specificity with the TST,
while those who have not received the vaccine
test at 98 % specificity [34];
– Those receiving BCG after infancy test at 60 %
specificity with the TST [34].
Wingate et al. BMC Public Health  (2015) 15:1201 Page 3 of 14
Since we had no way of determining how many adult
refugees had received BCG vaccination during or after
infancy, we assumed that one-third fit into each cat-
egory, with an average specificity of approximately 85 %.
Current protocol- domestic testing and treatment of
refugees with LTBI
In the current protocol, adult refugees are not screened
for LTBI overseas, but rather during post-domestic re-
settlement. However, refugees are tested for active dis-
ease during overseas screening, and in a manner similar
to a prior economic evaluation, we assume that all indi-
viduals with active TB overseas will have an abnormal
chest radiograph [33]. All individuals diagnosed with ac-
tive TB overseas are treated prior to U.S. arrival [5]. We
also assume that among our cohort with TB infection,
11 % will have inactive disease and an abnormal chest
radiograph [33]. Due to imperfect specificity of the chest
radiograph, a small portion of those with no infection
(5 %) will also have abnormal chest radiographs [35].
After resettlement, a small portion of those with abnor-
mal chest radiographs (1.5 %) will be diagnosed with ac-
tive TB within their first year of arrival, and we also
included this in our model [36].
We estimated that 76 % of all refugees present for do-
mestic medical exams at PHDs where the cost of a TST will
be incurred for those undergoing LTBI screening [7, 37].
The figure of 76 % is based upon data from a study that
evaluated how often PHDs submit forms to the CDC indi-
cating that they had performed any type of follow-up evalu-
ation among Class B1 refugees. The lower bound estimate
of 62.3 % was based upon the number of completed forms
received by CDC indicating that the follow-up evaluation
had been completed, and the upper bound estimate of
90.4 % was based upon the assumption that the follow-up
had been completed although the documentation was not
sent into the CDC.
The CDC maintains records of the tests performed
during follow-up examinations and stores the results of
these tests in the Electronic Disease Notification System
(EDN) for refugees with a Class B1 designation [6].
From a national perspective, unpublished EDN data in-
dicated that about 75 % of Class B1 refugees who pre-
sented for their domestic medical exam received LTBI
testing (Dr. John Painter, personal communication),
however the rate of testing is likely to vary across juris-
dictions [17–19]. It is likely that individuals who had a
Class B1 TB classification overseas received LTBI testing
more often than those with no TB classification, as
PHDs seem to place greater priority on testing those at
higher risk of developing active disease. We used varying
levels of domestic LTBI testing in our model due to un-
certainty in the extent of domestic LTBI testing and in
order to present more nationally representative results.
In situations where LTBI examinations occur frequently,
we assume 100 % LTBI testing for Class B1 refugees and
75 % LTBI testing for refugees with no TB classification.
To model situations where LTBI testing occurs at a
moderate rate, we assumed 75 % LTBI testing for Class
B1 refugees and 50 % LTBI testing for refugees with no
TB classification. In scenarios where LTBI testing occurs
more infrequently, we assumed that 50 % of Class B1
refugees receive LTBI testing and 25 % of refugees with
no TB classification receive LTBI testing.
Based upon previous research, we assumed that 77 %
of those who received post-arrival medical screening and
were diagnosed with LTBI accepted treatment in our
model [38]. Domestic LTBI treatment was modeled with
the 3HP regimen, which had documented completion
rates of 82 % [11]. We estimated that the medication
would be 93 % effective [39] in preventing future pro-
gression to active TB. For the 18 % of individuals who
did not complete treatment, we assumed that they com-
pleted 2 weeks of the regimen, with a corresponding ef-
fectiveness of 0 % [39].
Refugees who did not present for follow-up or declined
domestic treatment for LTBI, and those who did not
complete treatment were assumed to have a 0.1 % annual
probability of developing active TB disease [33, 40].
For the purposes of this model, no refugee diagnosed
and treated for active TB overseas received a TST at do-
mestic follow-up. This is because domestic PHDs interpret
documentation of prior TB treatment as an indication that
TSTs for LTBI would not be required. Thus, refugees
treated for active TB overseas incurred no additional do-
mestic costs related to LTBI screening or treatment.
Proposed protocol—overseas testing and treatment of
refugees with LTBI
The proposed protocol added a TST to the current med-
ical exam administered to all adult refugees before they
entered the United States. Since all adults currently re-
ceive a chest radiograph, the addition of LTBI testing is
not likely to change the sensitivity of overseas screening
for active TB. Individuals diagnosed with active TB dis-
ease are treated the same in the current and proposed
protocols. Even though relapse could occur after individ-
uals are treated for active disease overseas [41], the magni-
tude of this effect would not differ between the proposed
and current protocols. Thus, these cases are not included
in the estimates of TB cases occurring in the United
States. Refugees diagnosed with LTBI through a positive
TST result were offered the 3HP regimen prior to leaving
for the United States.
We assumed that 95 % of refugees diagnosed with
LTBI overseas would accept 3HP treatment, and the
only reason refugees would fail to complete treatment
was because of side effects (5 %) [11]. We based this on
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the fact that voluntary programs with presumptive treat-
ment of intestinal parasites for refugees while overseas
have high acceptance and completions rates [14]. We as-
sumed that refugees who ceased treatment did so after
completing 2 weeks of the regimen with a corresponding
effectiveness of 0 % [39].
As a follow up to the overseas protocol, we assumed
that 76 % [7] of refugees would present for domestic
follow-up in PHDs. The only refugees who would need
testing for LTBI during domestic follow-up would be
those with a negative TST overseas, because everyone
else with a positive TST would have either been treated
overseas, or would have already been ruled out for 3HP
due to medical contraindications. We did not adjust for
a booster effect in follow-up TST testing as the second
testing takes places months after the overseas testing. To
the extent that this occurs, it would lead to more false
positive being treated, but would not affect the number
of cases prevented. Once again, in our base case, refu-
gees who were Class B1 overseas would have a 75 %
chance of receiving LTBI testing at follow-up, and those
with no TB classification would have a 50 % chance of
receiving LTBI testing at follow-up.
If refugees tested TST-positive in the United States,
they would be offered domestic 3HP treatment. Of those
refugees testing positive, approximately 77 % [38] would
accept treatment, and 82 % of those starting treatment
would complete it [11]. For the 18 % of individuals who
did not complete treatment, we assumed that they com-
pleted 2 weeks of the regimen, with a corresponding ef-
fectiveness of 0 % [39].
Whether overseas or domestic, completion of treat-
ment with 3HP was assumed to have an efficacy of 93 %
[39] in preventing progression to active TB disease as es-
timated in a previous economic evaluation. Refugees
who did not present or declined domestic treatment for
LTBI and those who did not complete treatment were
assumed to have a 0.1 % annual probability of develop-
ing active TB [33, 40].
Cost overview
All costs were reported in 2012 United States dollars, and
were calculated from the health system and government
perspectives. Overseas and domestic costs included TST
kit prices, labor to administer 3HP DOT, and isoniazid
and rifapentine drug prices. Domestic costs also included
treatment for active TB cases. Drug costs were the same
in both domestic and international settings.
Costs of TST
For overseas estimates of TST prices, we first obtained
TST prices from a panel physician in Kenya as a base
observation. We used purchasing power parity (PPP) to
estimate what the price of the TST would be in other
countries included in the study [42]. Dividing the PPP
by the market exchange rate yields a national price level
which can be used to compare the price of a basket of
goods in one country with a reference country. For ex-
ample, because Kenya had a national price level of 0.44,
$0.44 spent in the Kenya purchased the same amount of
goods as $1.00 spent in the United States. We obtained
national price levels from the World Bank [42], and used
those to estimate the costs of TSTs in the other countries
in our study where refugees came from, although data was
not available from Syria. We averaged the price from the
remaining eight studies to obtain an estimate of $4.50 for
the cost of providing a TST to these refugees overseas. For
domestic estimates of TST prices, we referred to the Phy-
sician’s Fee and Coding Guide and used the lowest listed
price to represent the costs of a TST [43].
Wages and DOT labor costs
The country-specific cost for labor to administer 3HP was
determined using the most recently available (2011–2013)
United Nations (UN) pay scales at the time the study was
conducted. Each worker was assumed to be compensated
according to the UN General Service Category step 3 level
3 pay grade [44]. Five of the nine countries had wage data
corresponding to 2012, and we adjusted wages for the
other countries to 2012 using GDP deflator data obtained
from the International Monetary Fund [45]. We converted
these annual salaries to U.S. dollars using published ex-
change rates [46]. We used the weekly work hours listed
in each countries’ United Nations General Service cat-
egory salary scale to determine the wages per minute by
using a 52-week year. For example, Syria’s salaries are
based upon a 36-h work week [44], so we divided annual
wages by 112,320 min (52 weeks x 36 h per week x
60 min) to obtain the salary per minute.
The estimated DOT worker labor-time for providing
each dose of 3HP was obtained from CDC data describing
public health worker time (9.5 min) for administering and
documenting each dose of 3HP [47]. For domestic labor
costs, we assumed that DOT would be provided by licensed
practical nurses [39, 47], and used national average wages
from the Bureau of Labor Statistics [48]. The hourly wage
was divided by 60 in order to estimate the cost per minute
for each worker administering 3HP DOT to patients.
Refugee opportunity costs
Refugee time was not considered in overseas costs be-
cause refugees in camps are disallowed from salaried
work, sometimes for years, while waiting to depart for
the United States or another country. Undoubtedly, refu-
gee presence in camps in any country represented some
sort of consumption (food, medical care) and economic
activity to the country where refugees waited. However,
this economic activity was not comparable to that of
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residents or citizens. Refugees generally did not work,
and many had few resources, so their consumption con-
sisted of food, clothing, and shelter provided by a larger
organization.
We also did not calculate refugee opportunity costs
after the refugees arrived in the United States. Accord-
ingly, in a manner similar to a previous economic evalu-
ation, opportunity costs were not included for the
patients being treated for LTBI [33].
Cost of medications
At the time of this study, isoniazid was widely available
internationally, so we used global drug facility prices to
determine the cost of isoniazid for both overseas and do-
mestic LTBI treatment. Rifapentine was not widely avail-
able internationally; for example, it was not listed in
either the Global Drug Facility catalogue [49] or the
Management Sciences for Health International Drug
Price Indicator Guide [50]. Therefore, we determined
rifapentine costs using the most recent prices made
available to the federal government by the manufacturer
($1.00 per pill and $72.00 for the entire regimen) [51].
Costs of treating active TB
All individuals who developed active TB in the United
States were assumed to be treated domestically with the
cost accruing to the United States health care system.
The costs of treating active TB was derived from recent
a recent study and updated to 2012 dollars [52, 53].
Sensitivity analysis
We conducted one-way sensitivity analyses on several
model parameters. In our first sensitivity analysis, we
doubled the price for rifapentine to $2 per pill. This is
similar to the price seen in a previous study that evalu-
ated the cost of rifapentine in LTBI treatment regimens
[39, 47]. We also varied the overseas costs of the TST
screening from $3.50 to $5.15. This corresponded with
the highest and lowest prices found after applying the
country specific national price levels [42] to data for the
price of a TST administered by panel physicians in
Kenya ($4.80). We also varied TST specificity from 60 to
98 % in sensitivity analysis. This corresponded with the
potential range of TST specificity based upon the admin-
istration and timing of the BCG vaccine [34]. We also
included sensitivity analysis where we assumed that
77 % of refugees would accept 3HP overseas [38], and
82 % of refugees would complete 3HP overseas [11], as
this is similar to what we used in our domestic esti-
mates. In some cases, as many as 91 % of refugees have
accepted LTBI treatment domestically [23], and as many
as 91 % have also completed some type of LTBI treatment
[17], so we also included these parameters in sensitivity
analysis. In addition, we also included a sensitivity analysis
where we did not discount the costs or benefits of out-
comes occurring in the future as recommended by guide-
lines for conducting cost analysis in the U.S. [54].
We also included a sensitivity analysis where we added
the value of a statistical life (VSL) to account for add-
itional cost of premature mortality due to TB-related
deaths. The VSL does not measure the value of an indi-
vidual life, but rather the benefit due to reduced risk of
mortality in a group of people. Although there is still
considerable debate about the approaches used to value
excess risk of mortality in economic evaluations, we be-
lieve that the VSL is an acceptable approach to use in
cost-benefit analysis [55]. For modeling purposes, we es-
timated that 5.8 % of individuals that develop active TB
die from the disease as cited in in a previous cost-
effectiveness article [47]. We conservatively estimated
VSL at $5.2 million based upon a lower bound estimate
from the Department of Transportation [56] so that we
would not overstate the benefits of the screening pro-
gram due to the reduction risk of mortality.
We also included a scenario analysis where screening
would take place overseas, and individuals who were
TST positive overseas would be offered 3HP treatment
during domestic follow-up. Individuals who were TST
negative overseas would be tested again at domestic
follow-up, and those individuals who were TST positive
at follow-up would also be treated in the United States.
Finally, we included a scenario analysis where all refu-
gees in the United States receiving LTBI therapy would
be treated with 9 months of once-daily isoniazid. The
completion rate for 9 months of isoniazid was 72 %. We
averaged the completion rates for isoniazid from four
studies that assessed the completion rate of isoniazid in
refugees that had recently come into the U.S. [20–23].
Completed therapy with 9 months of isoniazid was as-
sumed to have the same efficacy (93 %) as 3HP in pre-
venting progression to active TB [11, 39].
Results
In our analysis there were three hypothetical cohorts
who tested TST positive at the following rates: high
(55 %), moderate (35 %), and low (20 %). These cohorts
had estimated LTBI prevalence values of 54, 27, and 7 %
respectively (Table 1). We rounded the estimates of LTBI
prevalence to the nearest whole number.
Cases of active TB prevented
Our analysis measured the cases of active TB prevented
over a 20-year period and we discounted costs and
health outcomes at 3 %. We incorporated discounting of
health outcomes in accordance with recommended prac-
tices, and we present the discounted values which show
the societal preference for receiving benefits sooner so
that less weight is placed upon cases prevented further
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in the future [22]. The number of active TB cases pre-
vented varied according to the level of domestic screen-
ing. In scenarios where domestic LTBI screening occurs
more frequently, implementation of overseas LTBI
screening prevented 370, 185, and 48 active TB cases in
U.S.-bound refugees from high, moderate, and low LTBI
prevalence cohorts respectively (Table 2). Where domes-
tic screening occurred at a more moderate rate, imple-
mentation of overseas LTBI screening prevented 440,
220, and 57 cases of active disease in refugees from high,
moderate, and low LTBI prevalence cohorts respectively.
When domestic LTBI screening was infrequent, overseas
LTBI screening programs prevented 509, 255, and 66 ac-
tive TB cases in U.S. bound refugees from high, moder-
ate, and low LTBI prevalence cohorts. We did not
include secondary transmission.
Proportion of refugees with LTBI completing treatment
Overseas screening and treatment programs would treat
a much higher proportion of refugees with LTBI when
compared to only domestic screening and treatment
(Fig. 1). For example, with overseas screening, approxi-
mately 9000 refugees with LTBI from the cohort with high
LTBI prevalence would not complete 3HP therapy during
the overseas screening process and domestic follow-up.
However, under the current protocol, where refugees are
only screened after arrival, over 40,000 would not
complete 3HP treatment due to the fact that only some
refugees would present for follow-up, and of these only a
limited number would be able to complete treatment.
Net costs or benefits from overseas screening
Overseas LTBI screening was associated with reduced
costs to treat active TB in the United States, and the cost
savings increased with prevalence of LTBI: $1 million
(low prevalence), $4 million (moderate), and $8 million
(high) (Table 3). As stated previously, total program
costs included treatment of active TB cases, and re-
sources used to screen for and treat LTBI including all
supplies for TST, DOT labor, and medications. When
looking at the base case with moderate levels of domes-
tic LTBI screening, there was a net program benefit for
overseas screening and treatment of refugees from high
($5.0 million benefit) and moderate ($1.8 million) LTBI
prevalence populations over the 20-year evaluation
period (Fig. 2). In the low LTBI prevalence population,
there was a net cost of $588,000. In the case that domes-
tic health departments screen more frequently, there is a
net program benefit for overseas screening and treat-
ment in refugees from populations with high ($4.6
million benefit) and moderate ($1.6 million benefit)
LTBI prevalence and a cost of $552,000 in refugees with
a low LTBI prevalence (Table 1). When domestic health
departments have less frequent LTBI screening, overseas
refugee LTBI screening and treatment programs resulted
in a net benefits of $5.4 million and $1.9 million for high
and moderate LTBI prevalence refugees respectively,
while there was a cost of $893,000 for refugees with a
low prevalence of LTBI.
Sensitivity analysis
In sensitivity analysis, the most influential parameters
were rifapentine price, TST specificity, and the inclusion
of VSL. After doubling the price of rifapentine to $2.00 a
pill which was similar to that in other studies [39, 47],
overseas screening had a net benefit of $2.3 million in
high LTBI prevalence populations (Table 4). However,
with the higher medication price, overseas screening had
an additional cost of approximately $56,000 in moderate
LTBI prevalence populations and $1.8 million in low
LTBI prevalence populations. If the TST specificity were
increased to 98 % from the baseline value of 85 %, the
program would produce cost savings of approximately
$5.4 million and $2.4 million in high and moderate LTBI
populations respectively. With the higher specificity, the
program would be nearly cost-neutral in low LTBI preva-
lence populations. We also included a sensitivity analysis
with a VSL value of $5.2 million in order to account for
the risk of premature mortality imposed by TB-related
deaths. With this sensitivity analysis, overseas screening
programs were cost-saving for all refugee populations:
$132.7 million (high prevalence), $65.6 million (moderate
prevalence), and $16.0 million (low prevalence).
We included a scenario analysis where we modeled pa-
tients being treated with isoniazid in the U.S. instead of
3HP. With this analysis there were net savings of $4.5
million in high LTBI prevalence populations and $1.5
million in moderate LTBI prevalence populations. There
was an additional cost of $694,000 in low LTBI preva-
lence populations with this scenario. We also evaluated
a scenario where refugees would receive initial screening
overseas, but all treatment would take place in the
United States. In this scenario analysis, overseas screen-
ing saved approximately $1.5 million for refugees from
high LTBI populations and approximately $288,000 in
refugees from moderate LTBI prevalence populations.
The program resulted in additional costs of $584,000 in
in low LTBI populations.
Discussion
Implementing an LTBI screening and 3HP treatment
program for refugees prior to their resettlement in the
United States would decrease the numbers of infectious
TB cases and would be cost-saving when implemented
for refugees that had a high or moderate prevalence of
LTBI. Our results show that this strategy could help make
progress towards elimination of active TB in the United
Wingate et al. BMC Public Health  (2015) 15:1201 Page 7 of 14
Table 1 Model parameters and assumptions for analysis comparing two programs for treating LTBI in U.S.-bound refugees
Parameter Value Source
Epidemiological Parameters
Age at screening 30 Assumption
Prevalence of active TB in refugee camps (Per 100,000)
High Prevalence 955 [28]
Moderate Prevalence 426 [28]
Low Prevalence 9 [28]
TST sensitivity 89 % [32]
TST specificity
Non BCG vaccinated populations 98 % [34]
BCG vaccinated during infancy only 92 % [34]
BCG vaccinated after infancy 60 % [34]
Overall TST specificitya 85 % calculated
Proportion with positive TST
High Prevalence 55 % [24–27]
Moderate Prevalence 35 % [24–27]
Low Prevalence 20 % [24–27]
True prevalence of LTBIb
High Prevalence 54 % calculated
Moderate Prevalence 27 % calculated
Low Prevalence 7 % calculated
Probability of abnormal chest radiograph with active disease 100 % [33]
Probability of abnormal chest radiograph with LTBI (inactive TB) 11 % [33]
Specificity of chest radiograph with no infection 95 % [35]
Probability of accepting 12-dose weekly isoniazid-rifapentine regimen overseas with positive TST 95 % [14]
Probability of completing 12-dose weekly isoniazid-rifapentine regimen overseas 95 % [11, 14]
Probability of active TB during first year of resettlement for Class B1 refugeesc 1.5 % [36]
Probability of presenting for domestic follow-up at U.S. health department 76 % [7]
Probability of receiving TST at domestic follow-up (Class B1) 75 % [assumption]
Probability of receiving TST at domestic follow-up (No TB class) 50 % [assumption]
Probability of accepting latent treatment in U.S. with positive TST 77 % [38]
Probability of completing 12-dose weekly isoniazid-rifapentine regimen in U.S. 82 % [11]
Effectiveness of completed 12-dose weekly isoniazid-rifapentine regimen in preventing active TB 93 % [39]
Effectiveness of partially completed 12-dose weekly isoniazid-rifapentine regimen in preventing
active TB
0 % [39]
Annual risk of progression to active TB with untreated latent disease 0.1 % [30]
Background Mortality Varies with age [23]
Cost Parametersd
Costs of TST used in overseas screening with hypothetical protocol
Base Case (average across originating countries) $4.50 Kenyan panel physicians and [42]
Lowest TST Cost $3.50 Kenyan panel physicians and [42]
Highest TST Cost $5.15 Kenyan panel physicians and [42]
Cost of TST in U.S. $24.00 [43]
Costs of 12 weekly 900 mg rifapentine doses through U.S. government $72.00 [51]
Costs of 12 weekly 900 mg isoniazid doses through Global Drug Facility $0.72 [49]
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States, especially among refugees and foreign-born resi-
dents where domestic TB prevalence is the highest.
Currently, foreign-born individuals in the United States
originating from countries with a high TB prevalence have
annual TB rates exceeding 40 cases per 100,000 for many
years after arrival [57, 58]. If we were not to discount the
benefits of our model, after the first year we estimated an
average annual TB rate of approximately 12 cases per
100,000 with overseas screening and about 42 cases per
100,000 without overseas screening in refugee populations
with a high LTBI prevalence (see Additional file 1).
This study estimated the public health impact on TB
reduction over a 20-year period after refugee resettle-
ment. For example, implementation of the overseas
screening in a cohort of 25,000 refugees arriving in 1 year
from high LTBI prevalence regions would result in about
110 infectious TB cases prevented over a 20-year period.
Similarly, in a cohort of 25,000 refugees from moderate
LTBI prevalence regions, implementation would prevent
about 55 infectious TB cases. Therefore, if the proposed
overseas screening program were adhered to for 20 years,
screening these two populations annually would prevent
over 3000 active TB cases in the United States. More-
over, based on the average number of contacts as re-
ported in a set of guidelines [59], at least 30,000 fewer
people would be exposed to an individual with active, in-
fectious TB. To be conservative, we did not consider the
effect of secondary transmission on TB costs in the
United States.
The total number of refugees resettling in the United
States fluctuates annually, but these results indicate that
overseas LTBI screening and treatment programs have
the potential to prevent thousands of TB cases and
would be cost-saving if used among refugees from high
and moderate LTBI prevalence regions. When refugees
emigrated from regions with high or moderate LTBI
prevalence, we estimated that the benefits of overseas
LTBI screening and treatment due to reducing the num-
ber of infectious TB cases were much greater than the
costs of implementing the program. Where the program
was implemented in regions with a low rate of LTBI
for refugees, there was also a reduction in the active
TB burden once refugees arrived in the United States,
but the expenditures for program implementation
Table 1 Model parameters and assumptions for analysis comparing two programs for treating LTBI in U.S.-bound refugees
(Continued)
Costs of labor to administer DOT during latent treatment
Average labor cost in refugee camp $13.40 [44, 47]
U.S. $38.70 [47, 48]
Costs of active TB case in U.S. $18,100 [52, 53]
BCG Bacille Calmette-Guerin, DOT Directly Observed Therapy, LTBI latent tuberculosis infection, TB tuberculosis, TST tuberculin skin test, U.S. United States;
aAssumes that refugees are approximately equally distributed between three categories affecting BCG specificity; bCalculated using the following formula:
(% test positive + specificity – 1)/(sensitivity + specificity −1); cClass B1 refugees indicates those with abnormal chest radiograph during overseas testing, but were
not diagnosed with active TB overseas; dAll costs reported in 2012 dollars;
Table 2 Net Benefit or (Cost) and Number of Tuberculosis Cases Diagnosed in the U.S. among a Cohort of 100,000 U.S. Bound

























Frequent High 632 262 370 $15,190,000 $10,568,000 $4,622,000
Moderate 316 131 185 $8,608,000 $6,959,000 $1,649,000
Low 82 34 48 $3,734,000 $4,286,000 ($552,000)
Moderate High 710 270 440 $15,389,000 $10,368,000 $5,021,000
(Base Case) Moderate 355 135 220 $8,376,000 $6,577,000 $1,799,000
Low 92 35 57 $3,181,000 $3,769,000 ($588,000)
Infrequent High 788 279 509 $15,588,000 $10,169,000 $5,419,000
Moderate 394 139 255 $8,143,000 $6,195,000 $1,948,000
Low 102 36 66 $2,628,000 $3,521,000 ($893,000)
LTBI latent tuberculosis infection, TST tuberculin skin test, U.S. United States
aAll costs in 2012 U.S. dollars; bCosts and benefits discounted at 3 % annually; cClass B1 refugees are those with abnormal chest radiographs in overseas
screening, frequent screening indicates LTBI testing offered to all Class B1 refugees at follow up medical examinations in U.S. and 75 % of all other refugees
receive LTBI testing, with moderate screening 75 % of Class B1 refugees and 50 % of all others receive LTBI testing, with infrequent testing, 50 % of Class B1
refugees receive LTBI testing and 25 % of all others receive LTBI testing; dHigh, moderate, and low prevalence correspond to 55, 35, and 20 % TST
positive respectively



























































Fig. 1 Proportion of Refugees with LTBI Completing Treatment with 12 Weekly Doses of Isoniazid and Rifapentine. LTBI = latent tuberculosis
infection; TST = tuberculin skin test; With no overseas screening, all screening and treatment for LTBI takes place in the United States. With




























































Fig. 2 Total Cost Incurred with Two Programs for Identifying and Treating LTBI in 100,000 U.S. -Bound Refugees. LTBI = latent tuberculosis
infection; TST = tuberculin skin test; U.S. = United States. With no overseas screening, all screening and treatment for LTBI takes place in the U.S.
With overseas screening, initial screening takes place overseas and TST positive refugees are offered treatment overseas. Costs incurred overseas
include the TST, 12 weeks of once-weekly rifapentine and isoniazid, and labor to administer the medications. Costs incurred domestically include
the TST, 12 weeks of once-weekly rifapentine and isoniazid, labor to administer the medications, and treatment of active TB patients
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Table 3 Types of Cost Incurred with Two Programs for Identifying and Treating LTBI in 100,000 U.S.-Bound Refugeesa
LTBI Prevalence















TST NA $450,000 NA $450,000 NA $450,000
DOT Labor NA $669,000 NA $426,000 NA $246,000
Medications NA $3,629,000 NA $2,312,000 NA $1,336,000
U.S. LTBI
TST $941,000 $415,000 $938,000 $605,000 $937,000 $746,000
DOT Labor $555,000 $110,000 $351,000 $118,000 $201,000 $124,000
Medications $1,043,000 $207,000 $660,000 $222,000 $377,000 $233,000
Active TB treatment $12,851,000 $4,887,000 $6,426,000 $2,445,000 $1,666,000 $634,000
Difference in active TB treatmente $7,964,000 $3,981,000 $1,032,000
Total program $15,389,000 $10,368,000 $8,376,000 $6,577,000 $3,181,000 $3,769,000
Net benefit or (cost)f $5,021,000 $1,799,000 ($588,000)
DOT directly observed therapy, LTBI latent tuberculosis infection, TB tuberculosis, TST tuberculin skin test, U.S. United States
aAll costs in 2012 U.S. dollars; bProportion TST positive; cAll LTBI screening and treatment takes place in U.S.; dRefugees screened with TST overseas, and TST
positive refugees are offered treatment with 12 doses of once weekly rifapentine and isoniazid; eRepresents the reduction in U.S. incurred active TB costs with
overseas screening and treatment programs; fA net benefit indicates that implementing overseas screening and treatment results in cost-savings while figures
enclosed in parentheses indicate that there is an additional cost associated with overseas screening and treatment
Table 4 Sensitivity Analysis of the Net Benefit or Cost and Cases of TB Prevented from Implementing Overseas LTBI Screening in
100,000 U.S.- Bound Refugeesa,b
LTBI Prevalence
High (55 %)c Moderate (35 %)c Low (20 %)c
Net benefit (Cost) Cases prevented Net benefit (Cost) Cases prevented Net benefit (Cost) Cases prevented
Parameter
Rifapentine price doubled $2,254,000 440 ($56,000) 220 ($1,767,000) 57
Overseas TST $3.50 $5,121,000 440 $1,899,000 220 ($488,000) 57
Overseas TST $5.15 $4,956,000 440 $1,734,000 220 ($703,000) 57
98 % TST specificity $5,397,000 440 $2,405,000 220 $189,000 57
60 % TST specificity $4,419,000 440 $829,000 440 ($1,830,000) 57
77 % acceptance rate 3HP overseas $3,758,000 323 $1,286,000 161 ($546,000) 42
82 % completion of 3HP overseas $4,025,000 360 $1,383,000 180 ($597,000) 47
91 % acceptance rate in U.S. $4,772,000 413 $1,680,000 207 ($610,000) 54
91 % completion of 3HP in U.S. $4,843,000 423 $1,713,000 212 ($606,000) 55
No discounting of cost or benefits $7,732,000 590 $3,155,000 295 ($237,000) 76
VSL Included $132,707,000 440 $65,641,000 220 $15,964,000 57
Screen overseas and treat in U.S. $1,463,000 165 $288,000 83 ($584,000) 21
Treat with isoniazid in U.S. $4,493,000 458 $1,513,000 229 ($694,000) 59
LTBI latent tuberculosis infection, TST tuberculin skin test; U.S. United States, VSL value of a statistical life
aValues reported in 2012 U.S. dollars
bA net benefit indicates that implementing overseas screening and treatment results in cost-savings while figures enclosed in parentheses indicate that there is
an additional cost associated with overseas screening and treatment
cProportion TST positive
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were higher than the reduction in costs to treat do-
mestic active TB cases.
This study has some limitations. First, the price of rifa-
pentine in countries where refugees originate from was dif-
ficult to determine because the medication had not been
used on a widespread basis in these countries and is not
yet approved in all countries. To address this issue, we con-
ducted a sensitivity analysis with a higher price that was
similar to that seen in other studies [39, 47]. Second, the
prevalence of LTBI was estimated through a fairly complex
set of estimations and calculations. However, this is an ap-
proved approach that has been used in other cost-
effectiveness studies [31, 32]. Because no test is available
that is 100 % accurate in determining whether a person
has LTBI [60], we used estimates of sensitivity and specifi-
city obtained from the literature. Third, comparing costs
and pricing (e.g., prices for goods or wages for labor) across
countries is always problematic because of currency differ-
ences, differential inflationary/deflationary trends, and cul-
tural perceptions of value. However, we used an across
country equivalency value of PPP recognized by WHO and
other international organizations. It was not possible to
calculate the opportunity costs of refugees overseas since
many countries prohibit refugees from working in the for-
mal economy. We omitted opportunity costs for refugees
both overseas and after arrival in the United States. This
should lead to conservative estimates of the economic effi-
ciency of overseas interventions because the opportunity
cost of refugee time is almost certainly greater after they
arrive in the United States than in the countries from
which they travel. We also did not have reliable informa-
tion on the proportion of refugees that had received BCG
vaccination. This has an important bearing on our analysis,
as an increase in the proportion of refugees with BCG vac-
cine would lead to more false positives due to decreased
TST specificity [34]. In order to explore the potential im-
pact of varying prevalence levels of BCG vaccine, we in-
cluded a sensitivity analysis where we modeled relatively
low and high levels of TST specificity.
In this study, we only considered screening with TST al-
though the interferon-gamma release assays (IGRAs) are
available. IGRAs have a higher specificity [34, 61, 62], and
their use results in fewer false-positives among persons
immunized with Bacillus Calmette-Guérin (BCG) vaccine,
one of the most frequently administered vaccines world-
wide. In general, IGRAs are more expensive to perform
than TSTs [63]. To assess the impact of IGRA’s costs on
the proposed screening program, we estimated a price at
which the benefit of reduced false-positives would out-
weigh the additional costs of IGRA. In order for overseas
screening to remain cost-saving, the price of the IGRA
overseas would have to be less than $55 in the high LTBI
prevalence populations and less than $23 in the moderate
prevalence populations. A more comprehensive analysis
of the costs of IGRA overseas and the impact on the cost-
effectiveness of LTBI screening for these refugee popula-
tions is beyond the scope of the current paper; however,
future research needs to address this issue.
In this analysis we evaluated the 12-dose weekly
isoniazid-rifapentine regimen although other regimens
like four months of once daily rifampin might also con-
ceivably be considered [11]. We focused on the 12-dose
weekly isoniazid-rifapentine regimen for three reasons:
1) It is most likely to be completed in the short time
span between the medical screenings and departure; 2)
The 12-dose weekly isoniazid-rifapentine regimen has
the highest completion rates so it is most likely to have
the greatest public health impact in terms of future TB
cases prevented [11]; and 3) The 12-dose weekly regi-
men would be logistically easier to administrate overseas
in refugee camps than once daily rifampin.
We found that LTBI screening and treatment among
refugees from moderate and high prevalence regions
would have considerable public health and economic
benefits. For refugees, such a program would reduce
their risk of developing active TB in the United States.
With the disease’s associated out-of-pocket and oppor-
tunity costs, this would result in one less obstacle to cre-
ating a new life in a country known for offering foreign
persons a new beginning. For the United States, the pro-
posed program would save costs relative to the existing
program and support CDC’s goal of TB elimination.
Conclusions
This study assessed the additional costs and benefits as-
sociated with adding screening for LTBI to the screening
that is already conducted for the screening done for ac-
tive, infectious TB. Screening for and treating LTBI was
logistically difficult in the past due to the limited time
frame between the refugees medical screening and de-
parture, however it is now more feasible with the 12-
dose weekly isoniazid-rifapentine regimen. Most of the
benefits of the program in terms of averted cases of TB
occurring in the U.S. would be realized in the years suc-
ceeding the refugee’s resettlement in the U.S. As such,
implementation of the program would represent an ini-
tial investment that would yield cost savings over time,
particularly for refugees from areas with a relatively high
or moderate prevalence of LTBI. In terms of public
health impact, the program would also be most efficient
if it focused on refugee from areas with a high preva-
lence of LTBI under a variety of scenarios.
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